Pulmo Pharma

About Pulmo Pharma

PulmoPharma ApS is a Danish clinical-stage pharmaceutical company established in 2014 that originated from Aarhus University. The company is focused on developing a novel treatment for life-threatening fungal lung infections, particularly those caused by Aspergillus fumigatus, which show increasing resistance to existing drugs. The primary target patient groups are individuals with azole-resistant Invasive Aspergillosis fumigatus and allergic bronchopulmonary aspergillosis (ABPA).

The company's lead product is Puldium™, a new inhalable combination drug designed for treating invasive aspergillosis in the lungs. This therapeutic is delivered directly to the lungs using a standard jet nebulizer. The combination treatment approach carries a low risk of developing further drug resistance. Pre-clinical and in-vitro studies, conducted in collaboration with institutions like the Department of Clinical Microbiology at Aarhus University Hospital, have demonstrated that Puldium™ outperforms current standard treatments against multiple resistant fungi types. This efficacy is critical as a swift and accurate diagnosis of the specific infecting fungus is difficult, often forcing clinicians to use a combination of potentially ineffective drugs with significant side effects.

PulmoPharma's business model is centered on the research and development of Puldium™ with the goal of it becoming the gold standard treatment for suspected fungal lung infections. The company has been supported by public and private investors and is now actively seeking partners, collaborators, and investors from larger medical companies to advance through pre-clinical and future human clinical trial phases. The company is currently conducting in-vitro/in-vivo studies and preparing for toxicology and Phase IIa studies to gather the evidence required for regulatory approval to begin human trials.